Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2007 by Rambam Health Care Campus.
Recruitment status was  Recruiting
Information provided by:
Rambam Health Care Campus Identifier:
First received: July 8, 2007
Last updated: October 21, 2010
Last verified: January 2007
A prospective, randomized, 3-arm parallel trial on 45 males with ED that were never exposed to PDE5i therapy (naïve patients) will be enrolled.In each group, every patient will receive three treatment regimes (Viagra®50mg & Levitra®10mg, Viagra®100mg, Levitra®20mg), in different sequences of administration in such a manner that eventually each patient will receive all regimes in a double- blinded fasion.Safety will be evaluated at pre- screening by measuring hourly vital signs (blood pressure, heart rate)for 4 consecutive hours after taking half-dose combination. Any decrease in blood pressure of 20 mmhg below baseline will exclude the subject from the study. Effcacy will be evaluated by questionnaires (IIEF, Quality of erection questionnaire, grade of erection scale, Sear, QVS and Sexual Encounter Profiles for each sexual event). Non-parametric statistical analysis of the collected data Comparing the 3 groups will be performed.

Condition Intervention Phase
Drug: Sildenafil, Vardenafil
Drug: Sildenafil
Drug: Vardenafil
Drug: Sildenafil & Vardenafil
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment

Resource links provided by NLM:

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • increase of 5 points or more in the IIEF erectile function domain [ Time Frame: 1 month ] [ Designated as safety issue: No ]

Estimated Enrollment: 46
Study Start Date: March 2007
Estimated Study Completion Date: June 2011
Estimated Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Viagra 100mg Drug: Sildenafil
Active Comparator: Levitra 20mg Drug: Vardenafil
Active Comparator: Viagra 50mg+ Levitra 10mg Drug: Sildenafil, Vardenafil
Sildenafil 100mg, vardenafil 20mg, combination of both half dosage.
Other Name: Viagra, Levitra
Drug: Sildenafil & Vardenafil
50mg & 10 mg

  Show Detailed Description


Ages Eligible for Study:   35 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Relationship with the same partner for at least 3 month
  • Age ranging between 35-65 years old
  • Sexually active, (minimal frequency of one sexual encounter per 2 weeks)
  • IIEF ED domain score 22 and below.

Exclusion Criteria:

  • Subjects with premature ejaculation as their main sexual complaint.
  • Subjects with severe cardiovascular disease in the past 6 months, including cardiac failure, myocardial infarction, unstable angina, stroke or transient ischemic attack, symptomatic or clinically significant cardiac arrhythmias including atrial fibrillation,
  • Subjects with Contraindications to PDE5i therapy. Namely patients receiving treatment with nitrate based medication or patients that for various reasons cannot take PDE5 inhibitors (severe hepatic diseases- cirrhosis or ALT (Alanine aminotransferase)>2x upper limit of normal), renal impairment (creatinine clearance > 30ml/min) or known hereditary degenerative retinal disorders such as retinitis pigmentosa. ,
  • Concomitant treatment with potent CYP3A4 and CYP2C9 inhibitors (e.g protease inhibitors ritonavir and saquinavir, ketoconazole, itrakonazole, miconazole, nefazodone, claritromycin, troleandomycin, erythromycin and cimetidine)
  • Subjects mentally unfit for the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00498680

Contact: Ilan gruenwald, MD 00972544474341
Contact: Yoram Vardi, Prof 0097248542819

Neuro-urology unit, Rambam Medical Center Recruiting
Haifa, Israel, 31096
Contact: Ilan Gruenwald, MD    0097248542882   
Contact: Yoram vardi, Prof    0097248542819   
Sponsors and Collaborators
Rambam Health Care Campus
Principal Investigator: Ilan Gruenwald, MD Israel Urology Association
  More Information

No publications provided

Responsible Party: Prof. Vardi Yoram, RAMBAM HEALTH CARE CAMPUS Identifier: NCT00498680     History of Changes
Other Study ID Numbers: 2431-ctil
Study First Received: July 8, 2007
Last Updated: October 21, 2010
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Rambam Health Care Campus:
Erectile Dysfunction

Additional relevant MeSH terms:
Cardiovascular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Therapeutic Uses
Urological Agents
Vasodilator Agents processed this record on November 30, 2015